Plant Name: Gleditsia japonica
Taxonomic Information:
Plant ID: NPO7631
Plant Latin Name: Gleditsia japonica
Taxonomy Genus: Gleditsia
Taxonomy Family: Fabaceae
Plant External Links:
NCBI TaxonomyDB:
66093
Plant-of-the-World-Online:
n.a.
Used in Medicines:
Country/Region:
South KoreaTraditional Medicine System:
Medicinal Functions:
Antitussive; Astringent; Expectorant; Haemostatic; Skin; VD
Geographical Distribution:
South Korea
Example Image
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| TSHR; NPSR1; | |
| ALPL; ALOX12; HSD17B10; NOX4; POLB; | |
| CDC25B; | |
| MET; AXL; FLT3; CDK1; PIM1; KDR; IGF1R; AURKB; | |
| CA12; CA7; CA4; | |
| NR1H4; | |
| MMP9; MMP1; MMP2; | |
| NFKB1; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: | CYP1B1; |
|---|
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Enzyme_unclassified | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P05186 | CHEMBL5979 |
| Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
| Metallo protease | MMP1 | Matrix metalloproteinase-1 | P03956 | CHEMBL332 |
| Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
| Nuclear hormone receptor subfamily 1 group H | NR1H4 | Bile acid receptor FXR | Q96RI1 | CHEMBL2047 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
| Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
| Protein Kinase | AXL | Tyrosine-protein kinase receptor UFO | P30530 | CHEMBL4895 |
| Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
| Protein Kinase | CDK1 | Cyclin-dependent kinase 1 | P06493 | CHEMBL308 |
| Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
| Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
| Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
| Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
| Protein Phosphatase | CDC25B | Dual specificity phosphatase Cdc25B | P30305 | CHEMBL4804 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0009987; cellular process | GO:0043066; negative regulation of apoptotic process | 4.996E-08 | 8.793E-05 | ALOX12, AURKB, AXL, CDK1, IGF1R, KDR, MMP9, NFKB1, NR1H4, PIM1 |
| BP | GO:0008283; cell proliferation | GO:0008284; positive regulation of cell proliferation | 6.906E-08 | 1.074E-04 | ALOX12, CDC25B, CDK1, FLT3, IGF1R, KDR, MMP2, MMP9, PIM1, TSHR |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 8.625E-07 | 7.223E-04 | CA12, CA4, CA7 |
| BP | GO:0008152; metabolic process | GO:0018108; peptidyl-tyrosine phosphorylation | 3.565E-06 | 1.988E-03 | AXL, FLT3, IGF1R, KDR, MET |
| BP | GO:0008152; metabolic process | GO:0046777; protein autophosphorylation | 4.604E-06 | 2.228E-03 | AURKB, FLT3, IGF1R, KDR, PIM1 |
| BP | GO:0050896; response to stimulus | GO:0071417; cellular response to organonitrogen compound | 8.969E-06 | 3.759E-03 | IGF1R, MMP2, NFKB1, NOX4, NR1H4, TSHR |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 1.329E-05 | 4.991E-03 | CA12, CA4, CA7 |
| BP | GO:0040011; locomotion | GO:0030335; positive regulation of cell migration | 1.699E-05 | 5.913E-03 | ALOX12, IGF1R, KDR, MET, MMP9, NOX4 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 2.449E-05 | 7.618E-03 | CA12, CA4, CA7 |
| MF | GO:0005488; binding | GO:0008144; drug binding | 2.992E-05 | 8.923E-03 | AURKB, AXL, CDK1, CYP1B1, FLT3, IGF1R, KDR, MET, NOX4, PIM1 |
| MF | GO:0060089; molecular transducer activity | GO:0005021; vascular endothelial growth factor-activated receptor activity | 3.364E-05 | 9.898E-03 | FLT3, KDR |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 4.067E-07 | 4.229E-05 | FLT3, MMP1, MMP2, MET, MMP9, NFKB1, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05206 | MicroRNAs in cancer | 1.424E-06 | 4.936E-05 | PIM1, CYP1B1, MMP9, MET, NFKB1, CDC25B |
| 09160 Human Diseases | 09161 Cancers | hsa05205 | Proteoglycans in cancer | 4.618E-06 | 9.606E-05 | MMP2, KDR, MMP9, MET, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05202 | Transcriptional misregulation in cancer | 2.564E-06 | 6.667E-05 | FLT3, MMP9, MET, NFKB1, IGF1R |
| 09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 1.160E-06 | 4.936E-05 | CA12, CA4, CA7 |
| 09160 Human Diseases | 09161 Cancers | hsa05219 | Bladder cancer | 1.782E-05 | 3.089E-04 | MMP1, MMP2, MMP9 |
| 09160 Human Diseases | 09161 Cancers | hsa05221 | Acute myeloid leukemia | 4.828E-05 | 7.173E-04 | FLT3, PIM1, NFKB1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04014 | Ras signaling pathway | 1.695E-04 | 2.204E-03 | KDR, MET, NFKB1, IGF1R |
| 09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 2.652E-04 | 2.758E-03 | MMP2, PIM1, NFKB1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04914 | Progesterone-mediated oocyte maturation | 2.426E-04 | 2.758E-03 | CDK1, CDC25B, IGF1R |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04151 | PI3K-Akt signaling pathway | 7.913E-04 | 7.481E-03 | KDR, MET, NFKB1, IGF1R |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| C00-D49: Neoplasms | Breast cancer | C50 | CDK1; IGF1R; KDR; FLT3; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | MMP1; |
| NA: NA | GIST | NA | FLT3; |
| C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR; |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | MMP2; |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | KDR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | MMP1; |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3; |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NFKB1; |
| C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR; |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | FLT3; |
| C00-D49: Neoplasms | Prostate cancer | C61 | FLT3; |
| K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET; |
| J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3; |
| C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R; |
| C00-D49: Neoplasms | Melanoma | C43 | KDR; |
| C00-D49: Neoplasms | AML | NA | KDR; FLT3; |
| C00-D49: Neoplasms | Renal cancer | C64 | KDR; |
| C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR; |
| A00-B99: Certain infectious and parasitic diseases | Anthelmintic | B89 | ALPL; |
| I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | MMP1; |
| C00-D49: Neoplasms | Cancer | C00-C96 | PIM1; MET; CDK1; IGF1R; KDR; NFKB1; FLT3; MMP9; MMP2; CDC25B; |
| C00-D49: Neoplasms | Multiple myeloma | C90 | IGF1R; |
| G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R; |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; IGF1R; KDR; AXL; |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | AURKB; FLT3; |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | MMP2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | IGF1R; |
| C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | MET; AURKB; IGF1R; KDR; FLT3; MMP9; MMP2; |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MMP9; |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA4; |
| C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR; |
| C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; |
| I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9; |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | KDR; FLT3; MMP2; |
| C00-D49: Neoplasms | Thyroid cancer | C73 | KDR; TSHR; |
| C00-D49: Neoplasms | Ovarian cancer | C56 | KDR; MMP2; |
| C00-D49: Neoplasms | Leukemia | C90-C95 | FLT3; |
| C00-D49: Neoplasms | Liver cancer | C22 | IGF1R; KDR; |
| C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR; |
| K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET; |
| C00-D49: Neoplasms | Colon cancer | C50 | FLT3; ALPL; |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | IGF1R; KDR; FLT3; MMP9; |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | KDR; |
| C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3; |
| C00-D49: Neoplasms | Gastric cancer | C16 | KDR; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET; |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | CDK1; IGF1R; |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | KDR; MMP2; |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; KDR; |
| NA: NA | Hematopoietic stem cell transplantation | NA | FLT3; |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | NPSR1; |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | AURKB; |
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR; |
| C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR; |
| C00-D49: Neoplasms | Metastasis | C00-C97 | AXL; |
| NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3; |
| I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET; |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | KDR; |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | KDR; MMP2; |
| C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR; |
| C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET; |
| H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R; |
| C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R; |
| C00-D49: Neoplasms | Glioblastoma | NA | FLT3; |
| C00-D49: Neoplasms | Gliosarcoma | NA | FLT3; |
| C00-D49: Neoplasms | Glioma | C71 | KDR; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | MMP2; |
| C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR; |
| C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR; |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Genetic disease | Q00-Q99 | ALPL; |
| C00-D49: Neoplasms | CLL | NA | FLT3; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
